IFNA1 and severe acute respiratory syndrome: Longitudinal studies revealed that while most patients with SARS-CoV infection had early IFN expression and the disease was resolved as the SARS-CoV-specific antibodies increased, those with severe diseases had initially delayed but later persistent IFN responses that were associated with reduced levels of SARS-CoV-specific antibodies and poor clinical outcomes (Cameron et al., 2007).